Moffitt at ASH

Drug Offers New Option for Patients With Rare Blood Disorders in ‘No Man’s Land’

Fedratinib is approved to treat myelofibrosis and could be effective in myelodysplastic/myeloproliferative neoplasms

Moffitt Study Explores Key Risk Factors To Better Personalize CAR T-Cell Therapy

The study analyzed ide-cel to help physicians intervene and reduce toxicities in multiple myeloma patients

Drug Aims To Improve Transplant Success for Myelofibrosis Patients

Study shows giving patients fedratinib is safe and could help reduce chance of relapse

Largest Comprehensive Study Compares Efficacy of CAR T Products for Multiple Myeloma

Cilta-cel demonstrates greater effectiveness than ide-cel but carries higher toxicities, study finds

New Treatment Combination Improves Outcomes for Relapsed or Refractory Large B-Cell Lymphoma

Patients who received the mosunetuzumab-polatuzumab combination had a 78% response rate

Moffitt Experts Conduct First Analysis on New Criteria for Chronic Myelomonocytic Leukemia

Study finds patients who were switched to a chronic myelomonocytic leukemia diagnosis based on the new criteria more so resembled myelodysplastic syndromes genetically.

New CAR T-Cell Therapy Shows Promising Results for Advanced Multiple Myeloma

Early trial results show high success rates and manageable side effects

Hard-to-Treat Lymphoma Patients Benefit From New Immunotherapy

AZD0486 demonstrates high response rates in relapsed/refractory diffuse large B-cell lymphoma, including patients who failed CAR-T therapy

Moffitt Researchers Find Breakthrough Treatment for Aggressive Blood Cancers

Promising combo therapy and innovative tracking techniques offer new hope for patients

New Study Suggests Socioeconomic Status Affects Access to Leukemia Transplant, Not Survival

Researchers point to access to care as a major issue for people in lower socioeconomic brackets

Study Reveals Key Insights Between New Blood Condition and Lower-Risk Myelodysplastic Syndromes

High-risk CCUS patients by CHRS and CCRS risk stratification tools have similar characteristics and outcomes to patients with lower-risk MDS

Moffitt Study Finds New Genetic Clues to Resistance in Multiple Myeloma Treatments

Study reveals genetic markers that predict treatment resistance, offering potential for more personalized therapy plans